Alliance for Pandemic Preparedness

December 23, 2020

ACTIV-3/TICO LY-CoV555 Study Group. (Dec 22, 2020). A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Category:

Topic:

Keywords (Tags): , , ,

A randomized clinical trial among patients hospitalized with COVID-19 that aimed to assess the effect of LY-CoV555, a neutralizing monoclonal antibody, was halted due to futility after 314 patients had undergone infusion with either the antibody or a placebo. Patients who received the antibody infusion did not have better clinical outcomes at day five than those who received the placebo. The authors note that studies of other neutralizing monoclonal antibody treatments will continue to move forward and that their clinical benefit may differ from that of LY-CoV555.

ACTIV-3/TICO LY-CoV555 Study Group. (Dec 22, 2020). A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2033130